文献速递脊柱关节炎

银屑病关节炎患者接受司库奇尤单抗治疗后中性粒细胞功能:细胞因子信号改变但宿主防御未受损

Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

19例活动性银屑病关节炎患者接受司库奇尤单抗治疗,随访48周,评估临床反应和外周血中性粒细胞功能,并与年龄性别匹配的健康对照比较。12周时75%患者达到PsARC反应、71%达到PASI 90反应;中性粒细胞吞噬杀伤、趋化、凋亡等宿主防御功能无改变,但表面标志物和转录组出现复杂变化。

要点

  • 12周时12/16(75%)患者达PsARC反应,36周时达100%;10/14(71%)达PASI 90反应。
  • 中性粒细胞活性氧生成、凋亡、趋化及调理化金黄色葡萄球菌吞噬杀伤在基线及治疗12周均与健康对照无差异。
  • 治疗中CD11b/CD18和CD63表面水平升高、CD16表达降低,早期应答者转录组显示细胞因子信号和趋化通路下调。

核心结论

  • 司库奇尤单抗治疗银屑病关节炎患者的中性粒细胞发生复杂性质变化,可能提示对局部和全身促炎细胞因子水平变化的反应性改变,但中性粒细胞的宿主防御过程未改变。

研究设计与样本

  • 研究纳入19例活动性银屑病关节炎患者,接受司库奇尤单抗治疗,每12周评估临床反应和外周血中性粒细胞功能,持续48周,并与年龄和性别匹配的健康对照比较。

主要发现

  • 12周时12/16(75%)患者达到PsARC反应,36周时达100%;10/14(71%)患者达到PASI 90反应。
  • 基线时银屑病关节炎患者中性粒细胞活性氧生成、组成性或细胞因子延迟凋亡、趋化及调理化金黄色葡萄球菌吞噬与健康对照无差异,治疗12周与基线相比这些功能也无差异。
  • 治疗期间中性粒细胞表面CD11b/CD18和CD63水平升高、CD16表达降低。
  • 在12周早期应答者亚组中,RNA测序显示转录组变化预测细胞因子信号和趋化通路下调、新生基因表达通路(包括翻译起始、mRNA分解代谢和翻译)上调。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Identifying that dysfunction of the IL-23/17 axis underlies PsA has led to the development of effective targeted therapies such as the IL-17A inhibitor secukinumab. As IL-17A stimulates the secretion of neutrophil chemoattractants, such as CXCL8 (IL-8), we examined the effect of secukinumab on neutrophil function in PsA. METHODS: Nineteen patients with active PsA were treated with secukinumab. Clinical response [PsA Response Criteria (PsARC) and Psoriasis Area and Severity Index (PASI)] and peripheral blood neutrophil function (apoptosis, receptor expression, phagocytosis/killing, chemotaxis and RNA expression) were measured at 12 week intervals for 48 weeks and compared with age- and sex-matched healthy controls. RESULTS: At 12 weeks, 12/16 (75%) patients had a PsARC response (100% at 36 weeks) and 10/14 (71%) achieved a 90% PASI response. At baseline, there were no differences in PsA neutrophil reactive oxygen species generation, constitutive or cytokine-delayed apoptosis, chemotaxis or phagocytosis of opsonized Staphylococcus aureus compared with healthy controls. Similarly, there were no differences in these functions from baseline to 12 weeks of therapy. However, surface levels of CD11b/CD18 and CD63 increased and expression of CD16 decreased during therapy. In addition, in a subgroup of early (12 week) responders to secukinumab, RNA sequencing revealed transcriptome changes predicting down-regulation of cytokine signalling and chemotaxis pathways and up-regulation of de novo gene expression pathways, including translation initiation, mRNA catabolism and translation. CONCLUSION: Complex changes in the properties of circulating neutrophils occur with secukinumab treatment in PsA that may indicate altered responsiveness to changes in both local and systemic levels of pro-inflammatory cytokines. However, host defence processes of neutrophils were unaltered.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cross AL, Hawkes J, Frankland H, et al. Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence. Rheumatology (Oxford). 2023. PMID: 36617171. doi:10.1093/rheumatology/kead007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。